GlassScriptPhysician profile
Maung Kyaw Oo
NPI 1194783670
$10,540.20
in general payments reported to CMS, 2019-2025
31 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,415 · 2020: $3,366 · 2021: $932 · 2022: $706 · 2023: $687 · 2024: $1,400 · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,071 · Education: $50.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,070.88 |
| Education | $50.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,650.17 | 2019-2025 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $1,171.06 | 2020-2025 | Airsupra, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,085.58 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Pulmonx Corporation | $602.67 | 2019 | |
| Insmed, INC. | $550.69 | 2019-2025 | Arikayce, Brinsupri |
| Glaxosmithkline, LLC. | $476.20 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| United Therapeutics Corporation | $350.17 | 2021-2025 | Tyvaso, Tyvaso |
| Amgen INC. | $254.51 | 2022-2025 | Tezspire |
| Genzyme Corporation | $189.51 | 2022-2025 | |
| Veran Medical Technologies, INC. | $147.40 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $138.85 | 2023 | Fujifilm |
| Davol INC. | $112.91 | 2021 | |
| Inogen, INC. | $97.63 | 2024 | |
| Grifols USA, LLC | $91.31 | 2021-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $88.13 | 2024-2025 | Dupixent |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $84.12 | 2020 | |
| Lilly USA, LLC | $58.85 | 2019-2025 | Zepbound |
| Mylan Specialty L.P. | $45.92 | 2019-2023 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $44.53 | 2019 | |
| Verona Pharma, INC. | $42.39 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $39.95 | 2019 | |
| Inspire Medical Systems, INC. | $35.71 | 2024 | Inspire |
| Actelion Pharmaceuticals US, INC. | $27.83 | 2025 | Opsumit |
| Resmed Corp | $26.76 | 2023 | |
| Fisher & Paykel Healthcare INC | $26.44 | 2024 | Fisher & Paykel Healthcare |
| Takeda Pharmaceuticals U.S.A., INC. | $21.46 | 2019 | |
| Gilead Sciences, INC. | $19.01 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.64 | 2021 | |
| Philips North America LLC | $15.52 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.91 | 2021 | |
| Electromed, INC. | $14.37 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maung Oo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.